HomeAI · summaries
Storia in 9 fonti
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
- ·
endpoints.news
AstraZeneca sinks on unexpected heart drug trial failure
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
- ·
economictimes.indiatimes.com
AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial
AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer…
- ·
milanofinanza.it
AstraZeneca crolla in borsa a Londra dopo il flop del farmaco Wainua: il titolo perde fino al 9% | MilanoFinanza News
Il gruppo farmaceutico britannico affonda dopo che lo studio clinico di fase avanzata sul farmaco Wainua non ha raggiunto l'obiettivo principale. Gli analisti rassicurano però…
- ·
statnews.com
AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.
- ·
independent.co.uk
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
- ·
latercera.com
AstraZeneca se derrumba en bolsa tras fracaso de ensayo clínico para fármaco cardíaco - La Tercera
Wainua no cumplió su objetivo principal en un estudio de fase avanzada para una rara condición cardíaca.
- ·
irishtimes.com
AstraZeneca shares slide 9% after heart treatment disappoints in trial
UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths
- ·
faz.net
AstraZeneca: Gescheiterter Herzmedikamenten-Test belastet
Fast 26 Milliarden Euro Börsenwert gehen verloren, nachdem ein Test ergeben hat, dass ein neues Herzmedikament praktisch wirkungslos ist. Doch trotz des Rückschlags bleibt…
- ·
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.